Graphite Bio/GRPH

$3.03

0.99%
-
1D1W1MYTD1YMAX

About Graphite Bio

Graphite Bio, Inc. is a clinical-stage gene editing company harnessing targeted gene integration to develop a class of therapies to cure a range of serious and life-threatening diseases. The Company has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).

Ticker

GRPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

-

Employees

120

Headquarters

South san francisco, United States

Graphite Bio Metrics

BasicAdvanced
$174.69M
Market cap
-
P/E ratio
-$2.24
EPS
-
Beta
-
Dividend rate

What the Analysts think about Graphite Bio

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analysts.
131.02% upside
High $7.00
Low $7.00
$3.03
Current price
$7.00
Average price target

Graphite Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-22.4M
-59.49%
Profit margin
0%
-

Graphite Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 55.07%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.44
-$0.43
-$0.97
-$0.39
-
Expected
-$0.49
-$0.33
-$0.31
-$0.25
-$0.13
Surprise
-10.81%
29.65%
215.96%
55.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Graphite Bio stock

Buy or sell Graphite Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing